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Abstract: Imipenem, a very potent
carbapenem derivative beta-lactam antibiotic,
has recently found a major place in the
treatment of antibiotic-resistant nosocomial
infections. However, a convulsive side effect
is seen in 0.2-3 percent of patients. Although
it is suggested that this effect is due to the
inhibition of gamma-aminobutyric acid
(GABA) mediated inhibitory transmission, no
study has been reported so far showing its
effect on the cerebral cortex free inhibitory
and excitatory amino acid levels.
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Twenty-one male TO albino mice were
divided into three equal groups and given
therapeutic (40 mg/kg/day) or excessive
(500
mg/kg/day)
doses
of

Introduction
Several classes of pharmacological agents have been
implicated in cases of drug-induced seizures, such as
antidepressants, neuroleptics, antihistamines, central
nervous system (CNS) stimulants, general and local
anaesthetic, and antimicrobial agents (1-3). The
epileptogenic properties of beta-lactams are well known.
Carbapenems are broad-spectrum beta-lactam antibiotics
that cover an absolute majority of all bacterial pathogens
that possess a cell wall. Imipenem, the first carbapenem
antibiotic introduced in the clinical field, is a derivative of
thienamycin containing a nuclear carbapenem ring
combined with cilastain, which inhibits the enzymatic
breakdown of imipenem in the kidney (4, 5). Seizures
related to imipenem have been described in both clinical
studies and experimental models. An incidence of seizure
of 0.2 to 3 percent has been noted among patients
treated with imipenem (6-8). It is reported that the
average time of onset for seizures in patients receiving
imipenem was seven days after the start of therapy (6).
De Sarro et al. (9) revealed that there was no significant
difference in the onset, duration and severity of seizures

Imipenem/cilastatine (I/C) or saline solution
intraperitoneally for 7 days. All animals in the
excessive dose group showed seizure-like
acivity with ataxia and loss of gait. However,
no differences in aspartate, glumatate,
glycine or GABA levels were seen on gas
chromatographic evaluation of the cerebral
cortexes of all three groups of animals, which
were dispatched on the 7th day. Therefore it
is suggested that imipenem exerts its
convulsive effect without causing any change
in neurotansmitter levels of barin, possibly by
effecting the neuronal receptors directly.
Key Words: Amino acid, imipenem, mice,
neurotoxicity.

with imipenem alone or in combination with cilastatin,
and that cilastatin by itself did not have convulsive effects.
Physiological and anatomical evidence suggets that
amino
acid
transmitters
carry
the
major
excitatory/inhibitory commands in the CNS and that other
types of CNS transmitters play more diffuse modulatory
roles. Gamma-aminobutyric acid (GABA) and glycine are
the principal inhibitory tranmitters, whereas glutamate
and aspartate are presumed to be the excitatory
transmitters (10). It was suggested that the induction of
beta-lactam-related
convulsions
was
caused
predominantly by the inhibition of GABA-mediated
inhibitory transmission (11-13). However, no research
has yet been reported on the free cerebral amino acid
levels. Therefore, this study was planned in order to
determine the free excitatory and inhibitory amino acid
levels in the cerebral cortex of mice reveiving therapeutic
or excessive doses of imipenem.
Materials and Methods
Animals: The study group consisted of twenty-one
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Table 1.

Free amino acid levels (µmol/g brain tissue)
Aspartate

Glutamate

Glycine

GABA*

Group I

0.08±0.03

0.21±0.09

0.11±0.06

0.24±0.08

Group II

0.04±0.02

0.27±0.23

0.16±0.03

0.18±0.04

Group III

0.06±0.02

0.38±0.24

0.26±0.16

0.17±0.07

>0.05

>0.05

>0.05

>0.05

p

Excitatory and inhibitory free
amino acid levels in mouse
brain
cortex
receiving
therapeutic or excessive doses
imipenem/cilastatine (I/C).

Results expressed as mean±SD
*GABA: gamma-aminobutyric acid
Group I: Animals receiving therapeutic dose (40 mg/kg/day)
Group II: Animals receiving high dose (500 mg/kg/day)
Group III: Animals receiving saline only (Control group)

male TO albino mice (Ege University Veterinary Research
Institute) weighing 20-28 grams. They were housed in an
air-conditioned room and fed a standard diet and water.

Drug and drug administration:
Imipenem/cilastatine (I/C) was obtained from Merck
Sharp & Dohme, İstanbul, Turkey. The drug was dissolved
in sterile water. Group I consisted of seven mice given
(I/C) 20 mg/kg/dose every 12 hours intraperitoneally for
7 days. Group II consisted of mice given I/C 250
mg/kg/dose every 12 hours intraperitoneally for 7 days.
Group III, the control group, consisted of seven mice
given physiologic saline (0.9% NaCl) intraperitoneally for
7 days.

Behavioural observations:
Animals were placed in their cages and observed for
60 minutes after intraperitoneal administration of I/C and
behavioural events were recorded.

Preparation of brain
chromatographic separation

tissue

for

gas

On the 7th day, all mice were killed by cervical
dislocation and decapitation. The brain was removed and
the cerebral cortex was separated, weighed and placed in
saturated picric acid (1/10) and 1ml of 2.5mM norleucine
was added as an internal standard. The tissue was
homogenized at 1400rpm using a glass-teflon
homogenizer and centrifuged at 3000 x g for 15
minutes. The supernatant was eluted through glass
columns (0.9 cm x 7 cm) containing Dowex 50 W x 12
and washed with bidistilled water. The amino acid fraction
was collected by passing 7 N NH4OH through the column
with a flow rate of 3 ml/minute and then lyophilized. The
lyophilizate was dissolved in 0.1 N HCl and transferred to
acetylation tubes with teflon-lined screw caps.
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Esterification occurred in 15 minutes at 100˚C with nbutanol 3N HCl, and acetylation in 5 minutes at 150˚C
with trifluoroacetic acid anhydryde. The amino acid
trifluoro acetyl n-butyl derivatives obtained were brought
to dryness under nitrogen and stored at -20˚C in
chloroform until gas chromatographic separation
occurred (14).

Amino acid analysis
A Pye-Unicam 104 gas chromatograph was used for
separation. The amino acids were separated in 2mm x
180cm glass columns containing 0.65% EGA chromosorb
W. NAW using a 6˚C/ min program between 60-120˚C.
The areas under the amino acid peaks were calculated
using an integrator (Spectra Physics Minigrator) and the
actual amino acid levels were determined (14).

Statistics
All values were expressed as mean±SD. Biochemical
data were analyzed by ANOVA (one way). Statistical
significance was defined at p values of less than 0.05.
Results
No seizure activity was observed in groups I and III.
However, all animals in group II receiving excessive doses
of I/C showed seizure-like activity (on days 3-7, average
5.7±1.3) within 15 minutes of receiving the injection and
lasted approximately 4 hours. Seizure-like activity (ataxia)
was characterized by loss of coordination of the legs and
was easily detected by the sudden cessation of walking or
running. Inhibitory and excitatory amino acid levels in the
cerebral cortex are summarized in Table 1. The
administration of therapeutic or excessive doses of I/C did
not alter neurotransmitter amino acid levels in the
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cerebral cortex, as all three groups had similar values
(p>0.05).
Discussion
Data obtained from both animals and humans support
the hypothesis that imipenem is a more potent inducer of
seizure activity than other beta-lactam antibiotics (9, 11,
14-16). The risk of neurotoxicity with imipenem has
become a factor impeding the use of high doses. Factors
known to increase the risk of seizure are excessive doses,
decreased renal functions, damage to the blood-brain
barrier, preexisting CNS diseases (stroke, tumours,
trauma), old age and concurrent use of drugs that are
nephrotoxic (e.g. cyclosporin) or that may lower the
seizure threshold (e.g. theophylline) (6, 7, 11).
In animal models, neurotoxic reactions have
frequently appeared when beta-lactam antibiotics were
applied to the brain surface or in the cerebral cisterns.
Epileptogenic reactions have also been observed following
the administration of very high systemic doses and it has
been revealed that neurotoxicity seemed to be related to
antibiotic concentration in brain tissue rather than to
cerebrospinal fluid concentrations (11, 15, 17). In our
study, seizure-like activity was observed in the excessive
dose group.
Imipenem CNS pharmacokinetics may play an
important role in inducing seizures because imipenem is
transported through the blood-brain barrier principally by
passive diffusion and its efflux from the CNS through the
blood-cerebrospinal fluid barrier is slow (18). Although
the main mechanism for the seizure activity of imipenem
cannot be easily determined, a possible pathogenic
mechanism is excitation of the CNS neurons by blocking
the synaptic activity of GABA, possibly at its receptor level
(11, 12). Williams et al. (13) showed that imipenem was
able to inhibit the binding of 3 H-labelled GABA to synaptic
membranes from rat brains, suggesting an interaction
with GABA receptors.
GABA is the dominant inhibitory neurotransmitter in
CNS and acts on at least two types of receptors, GABAA
and GABAB. Glycine classically has been considered to be
an inhibitory transmitter, like GABA, but with a more
limited distribution (especially in the hindbrain and spinal
cord) (10). Glutamate and aspartate have powerful
excitatory effects on neurons, and their interactions with
specific membrane receptors are responsible for many
neurological functions. They have four main receptor
subtypes: N-methyl-D-aspartate (NMDA), quisqualic acid,
kainic acid, and L-aminophosphonobutyric acid (10).

Excessive activation of glutamate receptors may mediate
neuronal injury and death. Excitotoxicity has been
suggested, a final common pathway for neuronal injury
due to diseases with diverse pathophysiological processes,
such as cerebral ischemia, anoxia, stroke, hypoglisemia,
trauma and epilepsy (19). Large amounts of glutamate
stored in presynaptic terminals and other intracellular
locations normally have rapid extracellular accumulation
in impaired cellular uptake during cerebral ischemia,
causing neuronal injury. Therefore, NMDA receptor
antagonists have been used in several experimental trials
in order to prevent cerebral injury after ischemia (19,
20).
De-Sarro et al. (21) have suggested an alternative
hypothesis on the involvement of other neurotransmitter
systems on imipenem-induced seizures. They
demonstrated that MK-801, a strong NMDA receptor
antagonist, showed prominent anticonvulsant activity
after both intraperitoneal and intracerebroventricular I/C
administration. Although imipenem-induced seizures
cannot be easily determined, potential interactions with
the receptors of the excitatory amino acid
neurotransmitters exist. In fact, antagonists of excitatory
amino acids are able to prevent seizures by increasing
their threshold. In addition, De-Sarro et al. (21) showed
that muscimol, a selective GABAA agonist, was able to
protect against seizures induced by imipenem following
intracerebroventricular I/C administration. However, in
our study no difference was found between the test
groups and the control group in excitatory and inhibitory
free amino acid levels in the cerebral cortex.
To our knowledge there has been no previous study
evaluating the free excitatory and inhibitory amino acid
levels in animals receiving imipenem. This is the first and
only study showing that no significant change occurs in
these levels in animals receiving therapeutic or high doses
of imipenem even though the latter group also showed
clinical seizure. Therefore, our data suggest that
imipenem-related neurotoxicity was neither due to
increased excitotoxicity nor to diminished inhibitory
amino acid levels in the cerebral cortex. The epileptogenic
properties of beta-lactams and imipenem may be related
to the inhibition of the GABA binding to its receptor sides.
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